MedPage Today on MSN4d
Sotatercept Helps the Sickest Patients With Pulmonary Arterial HypertensionCHICAGO -- Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk ...
The approval of revakinagene taroretcel (Encelto; Neurotech) addresses a significant unmet need for patients with macular ...
Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, spoke to the current state of research on revakinagene taroretcel ...
Orsini, a leader in rare disease pharmacy solutions, has been selected by Neurotech Pharmaceuticals, Inc., as the exclusive ...
Results from the Phase III ZENITH trial show that Winrevair lowered the risk of all-cause death, lung transplantation, and ...
Mirian Andino, 11, of Barnegat uses a motorized wheelchair to get around. Her parents need to raise $15,000 for a wheelchair-accessible van.
The biotech company, focused on developing treatments for chronic eye conditions, received Food and Drug Administration (FDA) ...
Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) functional class (FC) 3 or 4 at ...
As home lovers and HGTV fans, we've come to know and love many of the hosts and experts on our favorite shows. Here, we're ...
Quince Therapeutics, Inc. , a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback